ReviewJournal of pharmaceutical policy and practice2013
National medicines policies - a review of the evolution and development processes.
Review in Journal of pharmaceutical policy and practice, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- The need to update Ethiopia's national health and medicine policies: essential tools for informed decision-making in healthcare and the pharmaceutical sectors.Frontiers in public health · 2025Article
- Drawing up the public national Rational Pharmacotherapy Action Plan as part of social and health services reform in Finland: a bottom-up approach involving stakeholders.BMC health services research · 2024Article
- Unpacking the process of developing South Africa's national drug policy - lessons for universal health coverage.Journal of pharmaceutical policy and practice · 2024Article
- An exploratory study of the mandate and functions of national pharmaceutical services units: global trends and the cases of Côte d'Ivoire, Kenya, and Nepal.Journal of pharmaceutical policy and practice · 2024Article
- A desktop review of evaluation of implementation of national medicines policies in SADC countries.Heliyon · 2023Review
- The domestication of the African Union model law on medical products regulation: Perceived benefits, enabling factors, and challenges.Frontiers in medicine · 2023Article
- National medicines policy development, Saudi Arabia.Bulletin of the World Health Organization · 2022Review
- National adaptation and implementation of WHO Model List of Essential Medicines: A qualitative evidence synthesis.PLoS medicine · 2022Review
- Where National Medicines Policies Have Taken Us With Patient Involvement and Health Technology Assessment in Africa.Frontiers in medical technology · 2022Article
- Article
- Policy approaches to improve availability and affordability of medicines in Mexico - an example of a middle income country.Globalization and health · 2017Article
- Selection of essential medicines for South Africa - an analysis of in-depth interviews with national essential medicines list committee members.BMC health services research · 2017Article
- Pharmaceutical policy Part 1 The challenge to pharmacists to engage in policy development.Journal of pharmaceutical policy and practice · 2015Article
- Explaining the slow transition of child-appropriate dosage formulations from the global to national level in the context of Uganda: a qualitative study.Journal of pharmaceutical policy and practice · 2015Article
- The future of medicines use and access research: using the Journal of Pharmaceutical Policy and Practice as a platform for change.Journal of pharmaceutical policy and practice · 2014Article
- Medicines discarded in household garbage: analysis of a pharmaceutical waste sample in Vienna.Journal of pharmaceutical policy and practice · 2014Article
- Healthcare reform in the United States and China: pharmaceutical market implications.Journal of pharmaceutical policy and practice · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesContinuous provision of appropriate medicines of assured quality, in adequate quantities, and at reasonable prices is a concern for all national governments. A national medicines policy (NMP) developed in a collaborative fashion identifies strategies needed to meet these objectives and provides a comprehensive framework to develop all components of a national pharmaceutical sector. To meet the health needs of the population, there is a general need for medicine policies based on universal principles, but nevertheless adapted to the national situation. This review aims to provide a quantitative and qualitative (describing the historical development) study of the development process and evolution of NMPs.
methodsThe number of NMPs and their current status has been obtained from the results of the assessment of WHO Level I indicators. The policy formulation process is examined in more detail with case studies from four countries: Sri Lanka, Australia, former Yugoslav Republic of Macedonia and South Africa.
resultsThe number of NMPs worldwide has increased in the last 25 years with the highest proportional increase in the last 5-10 years in high-income countries. Higher income countries seem to have more NMP implementation plans available and have updated their NMP more recently. The four case studies show that the development of a NMP is a complex process that is country specific. In addition, it demonstrates that an appropriate political window is needed for the policy to be passed (for South Africa and the FYR Macedonia, a major political event acted as a trigger for initiating the policy development). Policy-making does not stop with the official adoption of a policy but should create mechanisms for implementation and monitoring. The NMPs of the FYR Macedonia and Australia provide indicators for monitoring.
conclusionsTo date, not all countries have a NMP since political pressure by national experts or non-governmental organizations is generally needed to establish a NMP. Case studies in four countries showed that the policy process is just as important as the policy document since the process must create a mechanism by which all stakeholders are brought together and a sense of collective ownership of the final policy may be achieved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.